Blockers of tumour necrosis factor-α: Mechanisms of action;Mechanizmy działania inhibitorów czynnika martwicy nowotworów α

Przeglad Gastroenterologiczny

Volumn 6, Issue 5, 2011, Pages 290-298

  Eder, Piotr ^a   Łykowska Szuber, Liliana ^a   Stawczyk Eder, Kamila ^a   Krela Kaźmierczak, Iwona ^a   Linke, Krzysztof ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Anti TNF agents; Apoptosis; Cytokines; Cytotoxicity; Inflammatory bowel diseases

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

BIOLOGICAL THERAPY; DRUG MECHANISM; ENTERITIS; HUMAN; MOLECULAR MECHANICS; REVIEW;

EID: 81855221213     PISSN: 18955770     EISSN: 18974317     Source Type: Journal    
DOI: 10.5114/pg.2011.25377     Document Type: Review

References (28)

1. Neuman MG. Immune dysfunction in inflammatory bowel disease. Trans Res 2007; 149: 173-86. (Pubitemid 46442010)
2. Bartnik W. Wytyczne postȩpowania w nieswoistych chorobach zapalnych jelit. Przegl Gastroenterol 2007; 2: 215-29. (Pubitemid 350200468)
3. Brennan FM, Chantry D, Jackson A, et al. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; 2: 244-7. (Pubitemid 19180612)
4. Elliott M, Maini R, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36: 1681-90. (Pubitemid 23360007)
5. Elliott M, Maini R, Feldmann M, et al. Randomised doubleblind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10. (Pubitemid 24317629)
6. Sandborn W. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. Rev Gastroenterol Disord 2005; 5: 10-8. (Pubitemid 40443992)
7. Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124: 177-85. (Pubitemid 36851350)
8. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Therapeut 2008; 117: 244-79.
9. Immunologia. Goła̧b J, Jakóbisiak M, Lasek W (red.). Wydawnictwo Naukowe PWN, Warszawa 2004.
10. Chowers Y, Sturm A, Sans M, et al. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohns Colitis 2010; 4: 367-76.
11. Horiuchi T, Mitoma H, Harashima S, et al. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology 2010; 49: 1215-28.
12. Maini R, Feldmann M. How does infliximab work in rheumatoid arthritis? Arthritis Res 2002; 4: S22-8.
13. Charles P, Elliott M, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti- TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999; 163: 1521-8. (Pubitemid 29352775)
14. Ulfgren AK, Andersson U, Engström M, et al. Systemic antitumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 2000: 43: 2391-6.
15. Gottlieb AB, Chamian F, Masud S, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005; 175: 2721-9. (Pubitemid 41113889)
16. Kruithof E, De Rycke L, Roth J, et al. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum 2005; 52: 3898-909. (Pubitemid 41798229)
17. Agarwal A, Panda S, Misra R. Effect of etanercept on matrix metalloproteinases and angiogenic vascular endothelial growth factor: a time kinetic study. Ann Rheum Dis 2004; 63: 891-92. (Pubitemid 38850471)
18. Valencia X, Stephens G, Goldbach-Mansky R, et al. TNF downmodulates the function of human CD4+ CD25hi T-regulatory cells. Blood 2006; 108: 253-61. (Pubitemid 43990636)
19. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004; 200: 277-85. (Pubitemid 39031247)
20. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301: 418-26. (Pubitemid 34429950)
21. Kaymakcalan Z, Beam C, Salfeld J. Murine model for assessing adalimumab, infliximab, and etanercept to prevent polyarthritis. Ann Rheum Dis 2003; 62 (Suppl 1): 136-7.
22. Fisher CJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996; 334: 1697-702. (Pubitemid 26193621)
23. Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-TNF agents on transmembrane TNFexpressing: comparison among infliximab, etanercept and adalimumab. Arthritis Rheum 2008; 58: 1248-57. (Pubitemid 351705913)
24. Mitoma H, Horiuchi T, Hatta N, et al. Infliximab induces potent anti inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 2005; 128: 376-92. (Pubitemid 40431090)
25. Di Sabatino A, Ciccocioppo R, Cinque B, et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004; 53: 70-7. (Pubitemid 38083013)
26. Van den Brande J, Braat H, van den Brink G, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124: 1774-85. (Pubitemid 36666774)
27. Bruns H, Meinken C, Scauenberg P, et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 2009; 119: 1167-77.
28. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent. N Engl J Med 2001; 345: 1098-104.